1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

With Prolia Rival In The Bag, China’s Luye Takes Aim At Xgeva Biosimilar

With Prolia Rival In The Bag, China’s Luye Takes Aim At Xgeva Biosimilar

 
• By Dean Rudge

Boan Biotech is continuing its ascent in Chinese biosimilars by filing another product with the country’s regulator.

Chinese flag
• Source: Shutterstock

China’s regulator has accepted for review local firm Boan Biotech’s biologics license application for its proposed biosimilar to Amgen’s Xgeva (denosumab) – months after the Luye Pharma Group, Ltd. subsidiary claimed the first biosimilar approved for marketing in the world for another version of the monoclonal antibody, Prolia.

BA1102, Boan’s Xgeva biosimilar candidate, has been accepted by the Chinese National Medical Products Administration’s Center for Drug Evaluation, based on comparative analytical, non-clinical, pharmacokinetics and clinical studies which “rigorously and

More from Biosimilars

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”